Improving mitochondrial metabolism by administering succinate and/or intermittent dichloroacetic acid (DCA) as PDK (and subsequent Akt/mTOR) inhibitors, or tauroursodeoxycholic acid (TUDCA), are viewed as promising agents in ischemic brain and neurodegenerative diseases [88,89]. The gene discussed is MTOR; the disease is neurodegenerative disease.